Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBE2M | P61081 | 12/20 | 0.41 |
| ▸ | DCUN1D1 | Q96GG9 | 12/20 | 0.41 |
| ▸ | CCR5 | P51681 | 2/20 | 0.39 |
| ▸ | GCK | P35557 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 2/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.38 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.38 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.38 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5579083 | 0.96 | HTR2A (0.41) | UBE2MDCUN1D1CCR5GCKBRAF | |
| SCHEMBL5579168 | 0.91 | KDR (0.43) | UBE2MDCUN1D1GCKBRAFKDR | |
| SCHEMBL13861265 | 0.85 | KDR (0.41) | BRAFKDRSLC6A5 | |
| SCHEMBL4326500 | 0.85 | KDR (0.46) | BRAFKDR | |
| SCHEMBL2255005 | 0.83 | KDR (0.37) | CCR5GCKBRAFKDR | |
| SCHEMBL3552886 | 0.82 | KDR (0.41) | BRAFKDR | |
| SCHEMBL4330057 | 0.82 | SLC6A5 (0.42) | CCR5GCKBRAFKDRSLC6A5 | |
| SCHEMBL13861193 | 0.81 | KDR (0.42) | BRAFKDR | |
| SCHEMBL2254995 | 0.81 | KDR (0.55) | CCR5BRAFKDR | |
| SCHEMBL4339311 | 0.81 | KDR (0.48) | BRAFKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | HGF, MET, FLT1 | UBE2M 4671/4885DCUN1D1 2514/4885CCR5 453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.